PharmAust Receives first $200k instalment for Phase 1 MND trial, appoints trial manager
- Clinical-stage biotechnology company PharmAust (PAA) receives over $201,000 under the first instalment payment from FightMND for its Phase 1 motor neuron disease trial
- The company has received more than $881,000 to examine the effects of monepantel in MND, also known as Lou Gehrig Syndrome or Amyotrophic Lateral Sclerosis (ALS)
- The company recently completed the manufacture of current Good Manufacturing Practice (cGMP) grade MPL, achieving the first milestone for the first instalment payment
- Further, the company appoints Alithia Life Sciences to manage the Phase 1 trial, and is fully funded through the Drug Development grant awarded by FightMND
- PAA shares are up 2.25 per cent, trading at 9.2 cents
